Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ALXN2050 in adults with generalized myasthenia gravis
2021-001229-26Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing ALXN2050 with Placebo (2 arms). Primary endpoint: Proportion of participants with MG-ADL response without rescue therapy. Started Oct 2021; status: terminated.
02
Drugs
vemircopan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2021-001229-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001229-26.